Products Research Area/Disease Metabolism CircuLex Anti-CML Human autoAntibody ELISA Kit
CircuLex Anti-CML Human autoAntibody ELISA Kit (Discontinued)
CircuLex Anti-CML Human autoAntibody ELISA Kit.

Specifications:
Description
We are sorry for the inconvenience; this product code has been discontinued.
The CircuLex Anti-CML human autoantibody ELISA Kit is used for the semi-quantitative measurement of IgG class anti-CML/Nε-(carboxymethyl) lysine human autoantibody in human serum and plasma. It can be used for 96 Assays.
Target: | CML |
---|---|
Product Type: | ELISA Kit |
Size: | 96 Assays |
Application: | ELISA |
Research Area / Disease: | Metabolism |
Species Reactivity: | Human |
Sensitivity: | better than 0.32 ng/mL of sample. |
Measurement Range: | Dilution factors need to be taken into consideration in calculating the antitoCML antibody concentration. Results exceeding antitoCMLtoautoantibody level of 2000 ng/ml, the sample should be repeated with dilution buffer. |
Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
Components
- Microplate
- 10X Wash Buffer
- Dilution Buffer
- Mouse Visfatin/PBEF Standard
- HRP conjugated Detection Antibody
- Substrate Reagent
- Stop Solution
Citations
- Koutroumani N et al. Protective mechanisms against oxidative stress and angiopathy in young patients with diabetes type 1 (DM1). 26, 309-17 (2013),
- Meloche J, et al., RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 31, 2114-2124 (2011)
References
- Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: Biochemistry 35: 8075 –8083,1996
- Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: Biochemistry 34: 10872 –10878,1995
- Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Kidney Int 48: 517 –526,1995
- Suzuki D, Yagame M, Jinde K, Naka R, Yano N, Endoh M, Kaneshige H, Nomoto Y, Sakai H: J Diabetes Complications 10: 314 –319,1996
- Imai N, Nishi S, Suzuki Y, Karasawa R, Ueno M, Shimada H, Kawashima S, Nakamaru T, Miyakawa Y, Araki N, Horiuchi S, Gejyo F, Arakawa M: Nephron 76: 153 –160,1997
- Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: Diabetologia 40: 764 –769,1997
- Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: Am J Pathol. 147: 654 –667,1995
- Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T: Atherosclerosis 141: 61 –75,1998
- Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Atherosclerosis 142: 67 –77,1999
- Kislinger T, Fu C, Huber B, Qu W, Taguichi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: J Biol Chem 274: 31740 –31749,1999
- Shibayama R, Araki N, Nagai R, Horiuchi S.; Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes. 1999 Sep;48(9):1842-9.
- Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E.; Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia. 2000 Nov;43(11):1385-8.
Related Content:
Brochures
Kinase Assay Kits